Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
The Kitasato Institute is active in the Biotechnology & Pharmaceuticals technology area and currently has 2 pending office actions. These actions are handled by 2 distinct examiners and are located within the assigned art units. This arrangement shows that the institute's current patenting activities are being evaluated across different administrative and technical groups within the patent office. The involvement of multiple examiners indicates a range of perspectives on the institute's active applications.
The busiest examiner for the portfolio is GRABER, JAMES J, who is responsible for 1 busiest examiner pending office action. With multiple pending office actions total and several distinct examiners involved, the workload is distributed across the assigned staff. This presence in distinct art units indicates that the institute's active applications involve multiple technical specialties within the pharmaceutical field. The management of different examiners across these units requires a coordinated prosecution strategy to handle the varying requirements of the individual reviewers while maintaining consistency across the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686638 | METHOD FOR PRODUCING INNER EAR STRIA VASCULARIS MARGINAL CELLS, CHEMICAL AGENT ASSESSMENT METHOD, AND CELL CULTURE FOR ASSESSING CHEMICAL AGENT | GRABER, JAMES J | — |
| 18566821 | KIT FOR DIAGNOSIS OF CANCER AND USE THEREOF | GOLDBERG, JEANINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686638 | METHOD FOR PRODUCING INNER EAR STRIA VASCULARIS MARGINAL CELLS, CHEMICAL AGENT ASSESSMENT METHOD, AND CELL CULTURE FOR ASSESSING CHEMICAL AGENT | GRABER, JAMES J | — |
| 18566821 | KIT FOR DIAGNOSIS OF CANCER AND USE THEREOF | GOLDBERG, JEANINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686638 | METHOD FOR PRODUCING INNER EAR STRIA VASCULARIS MARGINAL CELLS, CHEMICAL AGENT ASSESSMENT METHOD, AND CELL CULTURE FOR ASSESSING CHEMICAL AGENT | GRABER, JAMES J | 1631 | §103§112 | Final Rejection | — | Pending | Feb 26, 2024 |
| 18566821 | KIT FOR DIAGNOSIS OF CANCER AND USE THEREOF | GOLDBERG, JEANINE ANNE | 1682 | §101§112 | Non-Final OA | — | Pending | Dec 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe Kitasato Institute has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
James J Graber has the most, with 1 of The Kitasato Institute's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
